158 related articles for article (PubMed ID: 8556471)
1. Sustained cellular immune responses to Borrelia burgdorferi: lack of correlation with clinical presentation and serology.
Horowitz HW; Pavia CS; Bittker S; Forseter G; Cooper D; Nadelman RB; Byrne D; Johnson RC; Wormser GP
Clin Diagn Lab Immunol; 1994 Jul; 1(4):373-8. PubMed ID: 8556471
[TBL] [Abstract][Full Text] [Related]
2. Lymphoproliferative responses to Borrelia burgdorferi in patients with erythema migrans, acrodermatitis chronica atrophicans, lymphadenosis benigna cutis, and morphea.
Buechner SA; Lautenschlager S; Itin P; Bircher A; Erb P
Arch Dermatol; 1995 Jun; 131(6):673-7. PubMed ID: 7778918
[TBL] [Abstract][Full Text] [Related]
3. Serological follow-up after treatment of patients with erythema migrans and neuroborreliosis.
Hammers-Berggren S; Lebech AM; Karlsson M; Svenungsson B; Hansen K; Stiernstedt G
J Clin Microbiol; 1994 Jun; 32(6):1519-25. PubMed ID: 8077398
[TBL] [Abstract][Full Text] [Related]
4. Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans.
Aguero-Rosenfeld ME; Nowakowski J; Bittker S; Cooper D; Nadelman RB; Wormser GP
J Clin Microbiol; 1996 Jan; 34(1):1-9. PubMed ID: 8748261
[TBL] [Abstract][Full Text] [Related]
5. Erythema migrans and serodiagnosis by enzyme immunoassay and immunoblot with three borrelia species.
Stanek G; Breier F; Menzinger G; Schaar B; Hafner M; Partsch H
Wien Klin Wochenschr; 1999 Dec; 111(22-23):951-6. PubMed ID: 10666807
[TBL] [Abstract][Full Text] [Related]
6. [Lymphocyte proliferation test in cutaneous manifestations of Lyme borreliosis].
Breier F; Klade H; Stanek G
Wien Med Wochenschr; 1995; 145(7-8):170-3. PubMed ID: 7610666
[TBL] [Abstract][Full Text] [Related]
7. Cellular and humoral immune responses to Borrelia burgdorferi antigens in patients with culture-positive early Lyme disease.
Vaz A; Glickstein L; Field JA; McHugh G; Sikand VK; Damle N; Steere AC
Infect Immun; 2001 Dec; 69(12):7437-44. PubMed ID: 11705918
[TBL] [Abstract][Full Text] [Related]
8. Long-term serological follow-up of patients treated for chronic cutaneous borreliosis or culture-positive erythema migrans.
Lomholt H; Lebech AM; Hansen K; Brandrup F; Halkier-Sørensen L
Acta Derm Venereol; 2000; 80(5):362-6. PubMed ID: 11200835
[TBL] [Abstract][Full Text] [Related]
9. Molecular and serological diagnosis of Borrelia burgdorferi infection among patients with diagnosed Erythema migrans.
Kondrusik M; Grygorczuk S; Skotarczak B; Wodecka B; Rymaszewska A; Pancewicz S; Zajkowska J; Swierzbińska R; Hermanowska-Szpakowicz T
Ann Agric Environ Med; 2007; 14(2):209-13. PubMed ID: 18247452
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous manifestations of Lyme borreliosis.
Berger BW
Rheum Dis Clin North Am; 1989 Nov; 15(4):627-34. PubMed ID: 2685922
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of different IgG and IgM serum antibody responses to Borrelia burgdorferi after antibiotic therapy for erythema migrans: long-term follow-up study of 113 patients.
Glatz M; Golestani M; Kerl H; Müllegger RR
Arch Dermatol; 2006 Jul; 142(7):862-8. PubMed ID: 16847202
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans.
Smith RP; Schoen RT; Rahn DW; Sikand VK; Nowakowski J; Parenti DL; Holman MS; Persing DH; Steere AC
Ann Intern Med; 2002 Mar; 136(6):421-8. PubMed ID: 11900494
[TBL] [Abstract][Full Text] [Related]
13. Antibody responses to borrelia IR(6) peptide variants and the C6 peptide in Swedish patients with erythema migrans.
Tjernberg I; Sillanpää H; Seppälä I; Eliasson I; Forsberg P; Lahdenne P
Int J Med Microbiol; 2009 Aug; 299(6):439-46. PubMed ID: 19138558
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of test with antigen VlsE (C6) with tests with recombinant antigens in patients with Lyme borreliosis].
Zajkowska JM; Kondrusik M; Pancewicz SA; Grygorczuk S; Jamiołkowski J; Stalewska J
Pol Merkur Lekarski; 2007 Aug; 23(134):95-9. PubMed ID: 18044336
[TBL] [Abstract][Full Text] [Related]
15. Comparison of different Borrelia burgdorferi sensu lato strains for detection of immune response in patients with erythema migrans.
Merljak Skocir L; Ruzić-Sabljić E; Maraspin-Carman V; Lotric-Furlan S; Logar M; Strle F
Int J Med Microbiol; 2008 Jul; 298(5-6):493-504. PubMed ID: 17892971
[TBL] [Abstract][Full Text] [Related]
16. No detection of Borrelia burgdorferi-specific DNA in erythema migrans lesions after minocycline treatment.
Muellegger RR; Zoechling N; Soyer HP; Hoedl S; Wienecke R; Volkenandt M; Kerl H
Arch Dermatol; 1995 Jun; 131(6):678-82. PubMed ID: 7778919
[TBL] [Abstract][Full Text] [Related]
17. Comparison of four immunoserologic assays for detection of antibodies to Borrelia burgdorferi in patients with culture-positive erythema migrans.
Mitchell PD; Reed KD; Aspeslet TL; Vandermause MF; Melski JW
J Clin Microbiol; 1994 Aug; 32(8):1958-62. PubMed ID: 7989549
[TBL] [Abstract][Full Text] [Related]
18. Physician-diagnosed erythema migrans and erythema migrans-like rashes following Lone Star tick bites.
Masters E; Granter S; Duray P; Cordes P
Arch Dermatol; 1998 Aug; 134(8):955-60. PubMed ID: 9722725
[TBL] [Abstract][Full Text] [Related]
19. The impact of immunosuppression on erythema migrans. A retrospective study of clinical presentation, response to treatment and production of Borrelia antibodies in 33 patients.
Fürst B; Glatz M; Kerl H; Müllegger RR
Clin Exp Dermatol; 2006 Jul; 31(4):509-14. PubMed ID: 16716151
[TBL] [Abstract][Full Text] [Related]
20. Erythema migrans: three weeks treatment for prevention of late Lyme borreliosis.
Breier F; Kunz G; Klade H; Stanek G; Aberer E
Infection; 1996; 24(1):69-72. PubMed ID: 8852474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
